logo

For the Inventor, By the Inventor

Southbend, IN, United States of America

Paul E Gargan

USPTO Granted Patents = 13

 

Average Co-Inventor Count = 2.2

ph-index = 6

Forward Citations = 106(Granted Patents)


Location History:

  • Granger, IN (US) (1998 - 2000)
  • Southbend, IN (US) (1992 - 2001)

Company Filing History:

goldMedal12 out of 23 
 
American Biogenetic Sciences, Inc.
 patents
silverMedal1 out of 1 
 
American Biogenic Sciences, Inc.
 patent

Years Active: 1992-2001

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 6294173 - Methods for treating a tumor containing fibrin using a fibrin specific monoclonal antibody and compositions used therein (2001-09-25),
2. 6187593 - Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein (2001-02-13),
3. 6080384 - Methods for radionuclide-labeling of biomolecules and kits utilizing the (2000-06-27),
4. 5871737 - Methods for treating a fibrin encapsulated tumor using a fibrin specific (1999-02-16),
5. 5843690 - Immunoassay and kit for in vitro detection of soluble DesAABB fibrin (1998-12-01),
6. 5837540 - Method of producing fibrin-specific antibodies using soluble fibrin (1998-11-17),
7. 5723126 - Methods and compositions for therapeutic uses of a fibrin-specific (1998-03-03),
8. 5721122 - Method comprising immunization of antigen-free mice (1998-02-24),
9. 5487892 - Method for treating thrombotic disease using a fibrin specific (1996-01-30),
10. 5453359 - Immunoassay and kit for in vitro detection of soluble DesAABB fibrin (1995-09-26),
11. 5223410 - Method for production of antibodies utilizing an antigen-free animal (1993-06-29),
12. 5120834 - Fibrin-specific monoclonal antibody (1992-06-09),
13. 5091512 - Fibrinogen-specific monoclonal antibody (1992-02-25),

Title: Paul E Gargan: Innovator in Monoclonal Antibody Development

Introduction

Paul E Gargan is a notable inventor based in South Bend, Indiana, with a significant contribution to the field of biomedical research. He holds 13 patents, primarily focused on methods for treating tumors using monoclonal antibodies. His innovative approaches have the potential to enhance clinical diagnostics and therapeutics.

Latest Patents

Gargan's latest patents include groundbreaking methods for treating tumors that contain fibrin. One of his notable inventions is a method for the production of monoclonal antibodies utilizing an immunized germ-free animal. This invention not only provides a fibrin-specific monoclonal antibody but also outlines methods for using these antibodies in both in vitro and in vivo clinical settings. Another patent focuses on treating fibrin-encapsulated tumors using similar monoclonal antibodies, further emphasizing his commitment to advancing cancer treatment methodologies.

Career Highlights

Throughout his career, Paul E Gargan has worked with prominent companies such as American Biogenetic Sciences, Inc. and American Biogenic Sciences, Inc. His work in these organizations has allowed him to develop and refine his innovative techniques in antibody production and application.

Collaborations

Gargan has collaborated with esteemed colleagues, including Victoria A Ploplis and Julian R Pleasants. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Paul E Gargan's contributions to the field of monoclonal antibody development are significant and impactful. His innovative methods for treating tumors have the potential to revolutionize cancer therapies and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…